sitagliptin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus Non-insulin-dependent
Conditions
Diabetes Mellitus Non-insulin-dependent
Trial Timeline
Nov 26, 2008 → Sep 2, 2009
NCT ID
NCT00832624About sitagliptin
sitagliptin is a approved stage product being developed by Merck for Diabetes Mellitus Non-insulin-dependent. The current trial status is terminated. This product is registered under clinical trial identifier NCT00832624. Target conditions include Diabetes Mellitus Non-insulin-dependent.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus Non-insulin-dependent were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01449747 | Approved | Completed |
| NCT00853944 | Phase 3 | Terminated |
| NCT00832624 | Approved | Terminated |
| NCT00657280 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetes Mellitus Non-insulin-dependent